Palisade's stock collapses as sole asset flunks phase 2 GI trial in post-surgery patients

2023-08-09
FierceBiotech
临床2期临床结果临床3期临床失败
LB1148 is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes.
LB1148de Bio has ended deveserine protease inhibitorserine proteaselead and only drug in one of two potential indications after it failed to reduce adhesions in patients undergoing bowel resection surgery, sending the biotech’s stock into free fall.
Palisade Bioersion of the phase 2 trial of the protease inhibitor, dubbed LB1148, evaluated 22 patients who had surgery sinadhesionsith half receiving the drug and the other half receiving placebo. A look at the top-line data proved to the company that LB1148 “did not achieve the primary endpoint of reducing adhesions.”
The safety data don’t make for easy reading, eiprotease inhibitorproteasetotal of 16 seriousLB1148se events (SAEs) were reported in the LB1148 group, although the biotech pointed out that only three of these were related to the drug. The placebo group also saw a similar LB1148 with 14 SAEs.adhesions
“The company does not believe the safety data and efficacy results of the phase 2 PROFILE trial support further develoLB1148of LB1148 for reduction in intra-abdominal adhesions,” Palisade concluded in the Wednesday morning release.
LB1148 is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes with the aim of reducing intestiLB1148mage. The troubledintra-abdominal adhesionsy been through a couple of incarnations, initially enrolling 79 patients before it was paused in 2020 due to COVID-19.
LB1148ot yet the end of theserine protease inhibitorserine protease8, which is in a phase 3 trial by Palisade’s Chinese partner Newsoara to see whether the drug can accelerate the return of postoperative GI function. However, references to that trial were notable by their absence in this morning’s release.COVID-19
Trying to move investors’ attention oLB1148e future, CEO J.D. Finley promisePalisadehe biotech is “in tNewsoara of encouraging discussions that we believe will lead to pipeline expansion opportunities in high value indications in the GI space.”
“Our focus is now on completing these discussions in order to unlock opportunities and provide value for our shareholders,” the CEO added.
The vague reference to a brighter future clearly wasn’t enough to appease those shareholders, who sent the biotech’s stock plummeting 66% to 65 cents when the markets opened Wednesday from a Tuesday closing price of $1.94.
You can hardly blame them. Only three months ago, Palisade was “looking forward” to the phase 2 readout, which it said would be “integral in determining the most expedient clinical pathway for LB1148.” Palisade had already gone all in on LB1148, laying off 20% of staff last fall to conserve enough money to push the drug through the clinic.
It meant the company ended March with $13.3 millioPalisadeh and equivalents which, supplemented by $6 million from selling off some shares, had been expected to be enough to fund operations thrLB1148o 2PalisadeLB1148
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。